Adaptimmune LLC news

• Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells
• Data suggests that addition of AKT inhibitor (AKTi) during manufacture can remodel gene expression towards better proliferation or better cytotoxicity
• AKTi increases median persistence post-infusion, and in some patients, significant expansion is implied by higher peak recovery</

• SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year
• The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rate was 85%
• As of the data cut-off, afami-cel has shown a favorable benefit:risk profile
• Translational data confirm that afami-cel is active against MAGE-A4 expressing targets both&nb

• Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS
• The Company will host its first virtual medical symposium at CTOS
• Translational data from Phase 1 SURPASS trial to be presented at SITC

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will present clinical and translational data from the Phase 2 SPEARHEAD-1 trial at the Connective Tissue Onc

• Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform
• Adaptimmune will receive $150 million upfront, $150 million over the next five years in additional payments, and development, regulatory and commercial milestones payments potentially exceeding $

• One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff
• Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer at ILCA.

“We have seen significant antitumor